Our Collaborators

BeiGene

In August 2018, SpringWorks and BeiGene entered into a global clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of combining BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283) with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. A Phase 1b clinical trial is enrolling patients with advanced solid tumors that harbor mutations in RAS, RAF, and other MAPK pathway genes.

MapKure

MapKure is a clinical-stage company created in 2019 to develop precision medicines for patients with life-threatening diseases, with an initial focus on cancer. MapKure is jointly owned by SpringWorks and BeiGene, and is developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations, including V600 B-RAF mutations, non-V600 B-RAF mutations and RAF fusions. These mutations and fusions have been identified in a number of solid tumors to be drivers of cancer growth, including in non-small cell lung cancer, colorectal cancer, thyroid cancer and brain tumors.

GlaxoSmithKline

In June 2019, SpringWorks and GlaxoSmithKline entered into a global clinical collaboration agreement to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat with GlaxoSmithKline’s anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), BLENREP (belantamab mafodotin-blmf) (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.

Allogene

In January 2020, SpringWorks and Allogene entered into a clinical collaboration to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, with Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR TTM therapy in patients with relapsed or refractory multiple myeloma.

Janssen

In September 2020, SpringWorks entered into a clinical collaboration with Janssen Biotech, Inc. (Janssen) to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of combining SpringWorks’ investigational GSI, nirogacestat, in combination with Janssen’s investigational bispecific antibody targeting BCMA and CD3, teclistamab, in patients with relapsed or refractory multiple myeloma.

Children’s Oncology Group

In September 2020, SpringWorks and the Children’s Oncology Group (COG) entered into a collaboration to conduct a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors.